Forbion Strengthens US Presence, Hiring Biotech Industry Leader and Opening Boston Office
27 juin 2024 07h00 HE
|
Forbion
Josh Brumm, previously CEO of Dyne Therapeutics, appointed as General Partner at Forbion. Brumm to be located at Forbion's new Boston office.
Forbion announces first close of its new BioEconomy Fund I: backing biotech-enabled companies aiming to impact the future of our planet
20 juin 2024 01h25 HE
|
Forbion
Forbion announces the first close of its latest fund, Forbion BioEconomy Fund I (“Forbion BioEconomy"), at €75 million.
Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023
13 nov. 2023 09h55 HE
|
Forbion
Successful fundraising demonstrates value of Forbion platform, with multiple Forbion fund strategies supporting VectorY’s development since launch
Forbion co-leads $175 million Series B financing of Mariana Oncology as first investment of Forbion Ventures Fund VI
07 sept. 2023 06h45 HE
|
Forbion
Forbion co-leads oversubscribed Series B financing in next-generation radiopharmaceuticals companyFirst investment by its Forbion Ventures Fund VI, aimed at advancing highly impactful...
enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies
17 mai 2023 07h00 HE
|
Forbion
Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC’s sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth...
Forbion appoints Silva Deželan, PhD as Head of Impact and ESG
04 mai 2023 08h59 HE
|
Forbion
NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deželan PhD, as...
Forbion raises €1.35 billion across two funds
19 avr. 2023 01h00 HE
|
Forbion
Forbion’s largest fundraising to date€750 million raised in the final close of the Forbion Ventures Fund VI €600 million raised in the final close of the Forbion Growth Opportunities Fund II Brings...
Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim
04 août 2022 03h00 HE
|
Forbion
Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim Naarden, The Netherlands, 4 August 2022 – Forbion, a leading European life...
Forbion appoints Dr. Peter Høngaard Andersen as Operating Partner and Dr. Matt Cooper as Venture Partner
20 juil. 2022 02h00 HE
|
Forbion
Forbion appoints Dr. Peter Høngaard Andersen as Operating Partner and Dr. Matt Cooper as Venture Partner Naarden, The Netherlands – 20 July 2022 – Forbion, a leading European life sciences venture...
Forbion announces first close of Forbion Growth Opportunities Fund II at €470 million
09 juin 2022 02h00 HE
|
Forbion
Forbion announces first close of Forbion Growth Opportunities Fund II at €470 million New fund to invest in late-stage European life sciences companiesInvestors include Pantheon, pension funds PME...